Thomas Schinecker, Roche CEO (ddp images/Sipa USA/Sipa via AP Images)
July 25, 2024 07:16 AM EDTUpdated 07:31 AM
R&D
Pharma

Roche cuts two more TIG­IT tri­als, plans ac­cel­er­at­ed time­line for obe­si­ty drugs

Amber Tong

A year in­to Roche’s com­pre­hen­sive port­fo­lio re­view, the Swiss phar­ma said it has now tak­en out 25% of new drug can­di­dates from its pipeline. The …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ex­clu­sive: In­flu­en­tial De­mo­c­rat will op­pose Biose­cure Act ahead of House vote

Astel­las CEO talks fu­ture be­yond Xtan­di as Japan­ese drug­mak­er puts roots in Boston

Bridge­Bio sticks to script for AT­TR-CM as Al­ny­lam cleans up ‘ty­po’ sna­fu

Roche's Spark los­es CEO to RNA up­start; Ex-El­e­va­tion On­col­o­gy chief takes over at Af­fimed

Lil­ly inks obe­si­ty deal with seed-stage RNA start­up as its ge­net­ic med­i­cines ef­fort en­ters the spot­light

sponsored

How to se­cure full en­roll­ment and a 30x ROI: A con­ver­sa­tion with the CEO of the bou­tique en­roll­ment agency do­ing just ...

A service from the Financial Times